Milan Scheidegger is a visionary and integrative thinker with an academic background in medicine, neuroscience, philosophy, and psychiatry. He is driven by the passion to understand the nature of human existence from its molecular basis up to the level of phenomenal consciousness. As a resident physician at the Department of Psychiatry, Psychotherapy, and Psychosomatics (University of Zurich), he aims at developing „Transformational Psychotherapy“ as a novel and paradigm-changing treatment approach that advocates a shift from pharmacological substitution towards integrative transformational healthcare.

After successful completion of his MD-PhD training in functional and molecular neuroimaging at the Institute for Biomedical Engineering (ETH Zurich) he investigates the neurobiology and pharmacology of altered states of consciousness and their potential to facilitate psychological well-being. Together with Prof. Franz X. Vollenweider (Heffter Research Center Zurich) and Zen teacher Vanja Palmers, he recently completed a psilocybin neuroimaging study with long-term meditators in a meditation retreat setting. Together with Dr. Davor Kosanic he co-founded the non-profit social enterprise RECONNECT - Deep Consciousness Tools for Transformational Health Care. As junior research group leader he continues to research the potential of psychedelics such as ketamine, psilocybin, ayahuasca and DMT to facilitate therapeutic transformation.

Beyond empirical research, he earned an M.A. degree in History and Philosophy of Knowledge (ETH Zurich). Being deeply knowledgeable about biosemiotics, philosophy of mind, epistemology and phenomenology of consciousness, mindfulness and deep ecology, he developed a broader perspective on life. On his ethnobotanical expeditions to Mexico, Colombia and Brazil, he explored the traditional use of psychoactive plants in indigenous rituals.

He is current member of the Swiss Society for Psycholytic Therapy (SÄPT) and former scholar of the Swiss Study Foundation and received the Young Investigators Award from the Swiss Society of Biological Psychiatry (2013).